Padmanabh P. Bhatt - Nov 9, 2022 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
Sr. VP of IP, CSO
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Nov 9, 2022
Transactions value $
-$18,012
Form type
4
Date filed
11/14/2022, 04:00 PM
Previous filing
Aug 5, 2022
Next filing
Nov 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $6.47K +700 +42.58% $9.24 2.34K Nov 9, 2022 Direct F1
transaction SUPN Common Stock Sale -$24.5K -700 -29.86% $34.97 1.64K Nov 9, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -700 -9.33% $0.00 6.8K Nov 9, 2022 Common Stock 700 $9.24 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.90 to $35.145, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The option vested in four equal annual installments beginning on January 21, 2015.